Sanofi’s protein-based vaccine Nuvaxovid has topped Moderna’s next-generation messenger RNA shot mNexspike in a head-to-head trial assessing the tolerability of the two COVID vaccines.
Sanofi’s protein-based vaccine Nuvaxovid has topped Moderna’s next-generation messenger RNA shot mNexspike in a head-to-head trial assessing the tolerability of the two COVID vaccines.
Labs are seeing fewer applications from international students and researchers, and some doctoral students are considering leaving early.
Our lungs have evolved to heal from damage, but some smokers will suffer irreversible effects It used to be thought that the lungs couldn’t regenerate,” says …
The virus that is believed to be responsible for the deaths of three people and the illnesses of three others aboard a cruise ship over the …
The National Transportation Safety Board (NTSB) on Sunday said it will investigate a United Airlines plane that struck a pole on the New Jersey Turnpike. “The …